About this module
A new therapeutic option is now available to prevent renal failure in patients with type 2 diabetes.
In his lecture, Dr Bobby Chan presents the details of this new treatment for diabetes-related chronic kidney disease, including evidence and effectiveness. He will also outline where and when it should be incorporated into the GP management of this very common complication (renal disease) of this very common condition (type 2 diabetes).
Learning objectives
- Examine the evidence and effectiveness of finerenone for diabetes-related chronic kidney disease
- Identify when and where finerenone should be incorporated into the management of type 2 diabetes-related renal disease in a GP setting
Expert speaker
- Dr Bobby Chan | Endocrinologist, Diabetes Specialist and Weight Loss Physician
Accreditation
This activity is accredited for 0.5 hours in the Educational Activities (EA) category and 1 hour in the Measuring Outcomes (MO) category with the RACGP and ACRRM.
This educational initiative has been sponsored by Bayer Australia Ltd
Bayer Australia Ltd. 875 Pacific Hwy, Pymble NSW 2073. PP-KER-AU-0304-1. March 25
